Rezidivierende Lungenarterienembolie und koronare Thrombose bei Thrombozyth?mie

详细信息    查看全文

• 作者：Dr. F.-P. Pfabe (1)
  
• 关键词：Myeloproliferative Neoplasien ; JAK2 ; Mutation ; Thrombembolische Komplikationen ; Zytoreduktive Therapie ; Anagrelid ; Myeloproliferative neoplasms ; JAK 2 mutation ; Thrombembolic complications ; Cytoreductive treatment ; Anagrelide
• 刊名：Der Kardiologe
• 出版年：2013
• 出版时间：February 2013
• 年：2013
• 卷：7
• 期：1
• 页码：31-36
• 全文大小：750KB
• 参考文献：1. Griesshammer M, Petrides PE, Lengfelder E (2012) Chronische Myeloproliferative Erkrankungen. http://www.dgho-onkopedia.de/onkopedia/leitlinien
  2. Petrides PE, Grie?hammer M, Lengfelder E (2012) Essenzielle (oder prim?re) Thrombozyth?mie (ET). http://www.dgho-onkopedia.de/onkopedia/leitlinien
  3. Griesshammer M, Lengfelder E, D?hner et al (2007) Essenzielle Thrombozyth?mie. Dtsch Arztebl 104 (34-5):A2341-346
  4. Petrides EP (2006) Prim?re Thrombozyth?mie: Diagnose und Therapie. Med Klein 101:624-34 CrossRef
  5. Kunz I, Spada S, Sütsch G, Ruggierie F (2005) Belastungsinduzierte Schmerzen im linken Arm und erh?hte Thrombozytenzahl. Praxis 94:599-03 CrossRef
  6. Baxter EJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloprolliferative disorders. Lancet 365:1054-061
  7. Lambert J-F, Duchosal MA (2007) H?matologie: Myeloproliferative Syndrome -Eine Kinase folgt der anderen. Schweiz Med Forum 7:11-3
  8. Kralovics R et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779-790 CrossRef
  9. Doesch C et al (2008) Challenges in the treatment of patients with essential thrombozythemia and acute coronary syndrome. J Thromb Thrombolysis 25:193-97 CrossRef
  10. De Stefano V (2010) Increased risk of recurrent thrombosis in patients with essential thrombozythemia carring the homozygous JAK2 V617F mutation. Ann Hematol 89:141-46 CrossRef
  11. Arrelano-Rodrigo E (2006) Increased platelet and leucocyte activation as contributing mechanismus for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 91:169-75
  12. Chang H et al (2006) Coronary artery intervention after cytostatics treatment in unstable angina in unstable patient with essential thrombozythemia. A case report and literature review. Korean J Intern Med 21:146-49 CrossRef
  13. Terrada H, Satoh H, Uehara A (2000) Multivessel coronary thrombosis, acute myocardial infarction, and now reflow in a patient with essential thombocythaemia. Heart 83:e10 CrossRef
  14. Andrew I, Schafer MD (2006) Thrombocytosis: When is an incidental finding serious? Cleve Clin J Med 73:767-74 CrossRef
  15. Harrison CN et al (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Eng J Med 353:33-5 CrossRef
  
• 作者单位：Dr. F.-P. Pfabe (1)
  
  1. Klinik für Gef??medizin, Asklepios Klinikum Uckermark GmbH, Auguststr. 23, 16303, Schwedt, Deutschland
  

文摘

Essential thrombocythemia (ET) is an entity of chronic myeloproliferative neoplasms (MPN) with onset in old age. A diagnosis by exclusion is based on molecular and non-molecular criteria. Platelet count, bone marrow histology and Janus kinase2 (JAK 2) status are required for diagnosis confirmation (WHO criteria). Complex disorders of platelet and hemorheological function and the JAK 2 mutation dominate the variable disease with thrombotic and hemorrhagic complications. Age, platelet count and thrombotic/hemorrhagic events represent high risk criteria. The use of anagrelide (cytoreductive) needs cardiac risk assessment and monitoring due to potential cardiac side effects.